CCTG IND.240 - IPROC

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

---

Population: Gyne - Serous Ovarian Cancer

Line of therapy: 1st or 2nd for platinum-resistant disease

Intervention: Further treatment arms TBD

Key Inclusion Criteria

1. Patients (>=18 yrs old, ECOG PS 0-1),

2. Life expectancy >= 3 mo.

3. must have platinum resistant high-grade serous carcinoma of ovarian, fallopian tube or peritoneal origin defined as progression within the last 6 mo. of last platinum containing chemo.

4. Histological confirmation of original primary tumour.

5. Measurable disease per RECIST 1.1.

6. No limit on prior regimens for platinum sensitive disease but may not have received more than 1 cytotoxic chemotherapy regimen for platinum-resistant disease.

7. Prior treatment with immune checkpoint inhibitors is allowed provided it was not discontinued due to severe/recurrent severe toxicity.

8. May have received non-cytotoxic therapies excluding the agents targeted by the planned substudy.

9. Consent to pre/on treatment tumour biopsies.

   
   

Key Exclusion Criteria

1. No uncontrolled/serious illnesses or medical conditions which would not permit the patient to be managed per protocol.

2. No central nervous system metastases.

3. No prior autoimmune or inflammatory disorders within the past 3 yrs.

Sponsor: CCTG

CRP Contact: martha.elbebawy@ladydavis.ca

CRP PI: Dr. S. Lau

Status: Open to accrual, however treatment arms TBD